Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Flow diagram showing study population of Chinese patients with type 2 diabetes mellitus and reasons for exclusion Yang X et al. CMAJ 2008;179:

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Michal Vrablík Centre for Preventive Cardiology 3 rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague Czech Republic.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Baseline Prevalence of Metabolic Syndrome and Individual Components Among 4258 Older Adults Dariush Mozaffarian, et al. Arch Intern Med. 2008;168:

Study Flow Diagram Holvoet P, et al. JAMA 2008;299: The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Serum Selenium Levels and All-Cause, Cancer, and.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.

Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Oxidation-Specific Biomarkers, Prospective 15-Year.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of the Atkins, Ornish, Weight Watchers,

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

The SPRINT Research Group

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Copyright © 2009 American Medical Association. All rights reserved.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Copyright © 2012 American Medical Association. All rights reserved.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

TNT: Baseline and final LDL cholesterol levels

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

TNT Study: Baseline Characteristics of the Patients

Fellström BC, et al. N Engl J Med 2009;360:1455-7

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Baseline Characteristics of the Study Cohort*

Classification of statins/dosages according to the attainable

Plus–minus values are means ±SE

Daan Kromhout, et al. NEJM epub August 29, 2010

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics of the Subjects

Characteristics of the Patients at Baseline*

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.

Baseline Characteristics of the Study Participants

Baseline Characteristics of the Subjects*

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Relative Risk of Myopathy Associated with Selected Baseline Characteristics among 6031 Participants Assigned to 80 mg of Simvastatin Daily in SEARCH The.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Baseline Characteristics of the Patients – Part I

Baseline Characteristics by hs-CRP

RECORD Study: Enrollment and Outcomes

The ACCORD Study Group. NEJM 2010; Epub March 14

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Baseline Characteristics of the Trial Participants, According to Study Group Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Occurrence of Venous Thromboembolism According to Study Group Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Cumulative Incidence of Venous Thromboembolism in the Rosuvastatin and Placebo Groups Panel A shows the incidence of any venous thromboembolism, Panel B the incidence of unprovoked venous thromboembolism (i.e., occurring in the absence of a known malignant condition, trauma, hospitalization, or surgery), and Panel C the incidence of provoked venous thromboembolism (i.e., occurring in patients with cancer or during or shortly after trauma, hospitalization, or surgery). The P values were calculated on the basis of a likelihood-ratio test of the effect of rosuvastatin, with the use of a proportional-hazards model. Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Effects of Rosuvastatin on the Risk of Venous Thromboembolism, According to Baseline Characteristics of the Study Participants Hazard ratios for the rosuvastatin group as compared with the placebo group are shown, with the size of each black square proportionate to the number of participants in the subgroup in whom venous thromboembolism developed; the horizontal lines indicate 95% confidence intervals. The dashed vertical line indicates the overall hazard ratio for the entire trial cohort. The incidence rate in the placebo group is the number of events per 100 person-years of follow-up. Not shown are P values for tests of interaction between rosuvastatin and subgroup variables, each of which was nonsignificant (P>0.10). For each subgroup, the number of patients for whom data were available is shown. Data were missing for some participants in some subgroups. The metabolic syndrome was defined according to consensus criteria of the American Heart Association and the National Heart, Lung, and Blood Institute.27 To convert the values for cholesterol to millimoles per liter, multiply by To convert the values for triglycerides to millimoles per liter, multiply by The body-mass index is the weight in kilograms divided by the square of the height in meters. CRP denotes C-reactive protein, HDL high-density lipoprotein, and LDL low-density lipoprotein. Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub]

Occurrence of Venous Thromboembolism, Cardiovascular Disease, and Death According to Study Group* Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]